I was having drinks with an old friend last month—he runs procurement for a hospital network in Miami—when he said something that made me stop mid-sip.
“You know what’s insane? We fight tooth and nail with pharma companies over drug prices. We push back hard on medical device makers. We negotiate aggressively with insurers. But there’s this whole category where we don’t even bother anymore. We just accept whatever they charge.”
I put down my glass. “Which category?”
“Consumables. The stuff nobody thinks about. Dialysis supplies, surgical kits, blood collection tubes. We use thousands of units every single day, and there are literally two or three companies in the entire world making each product. They raise prices 8-12% every year like it’s written into the contract. We complain politely. They smile. We pay. Because what’s the alternative?”
That conversation stuck with me.
I started digging. Pulled earnings transcripts. Read through 10-Ks. Talked to more hospital administrators, procurement specialists, medical device reps. And what I found is possibly the most underappreciated structural opportunity in healthcare right now.
While the market obsesses over GLP-1 drugs and AI diagnostics, there’s a tier of medical consumables companies that are:
Raising prices 8-15% annually without meaningful resistance
Operating in effective duopolies with 70-90% combined market share
Generating 60-80% gross margins on products costing $5-50 to manufacture
Building switching costs so prohibitive that customers stay locked in for decades
Trading at 15-20x earnings despite 10-15% organic growth and expanding margins
The reason nobody talks about them? They make unglamorous products. Dialysis filters. Surgical staplers. IV catheters. Endoscopy accessories.
But unglamorous is exactly what makes them extraordinary.
Why Wall Street Systematically Ignores the Best Healthcare Assets
Here’s what gets analysts excited: breakthrough drugs, revolutionary devices, disruptive platforms.
Everyone wants to find the next Ozempic. The next robotic surgery system. The next AI diagnostic that changes everything.
I understand the appeal. Those stories are compelling. They generate headlines and spectacular pitch decks.
But Wall Street systematically undervalues something far more powerful: mundane products with impenetrable competitive moats that generate cash flow like ATMs.
Think about how hospitals actually function operationally. Every single day, they require:
Thousands of syringes, needles, and catheters
Hundreds of surgical kits with specialized instruments
Dozens of dialysis filters for chronic kidney patients
Blood collection tubes for every lab test ordered
Endoscope accessories for every GI procedure
Wound care products for every surgical case
IV solutions for every admitted patient
These aren’t discretionary purchases. These aren’t products hospitals can substitute or delay. These are mission-critical consumables used once and discarded.
And here’s the structural advantage that creates enormous value: once a hospital standardizes on a supplier, switching becomes virtually impossible.
The reasons are fundamental to how healthcare delivery works:
Clinical protocols are built around specific products. Nurses and physicians are trained on exact procedures using exact equipment. Changing suppliers means retraining thousands of clinical staff members—a massive operational disruption.
Regulatory approval is byzantine. Every product requires extensive documentation, validation testing, committee approvals. The process takes 12-18 months minimum to switch suppliers for a major consumable category.
The economic incentive doesn’t justify the operational risk. You might save 5-10% on product cost—but you risk procedure delays, staff errors, patient complications. No hospital CFO wants to explain why they disrupted clinical operations to save $200,000 annually.
Products represent a tiny fraction of total procedure costs. A $40 surgical stapler is used in a $15,000 surgery. A $25 dialysis filter is part of a $400 treatment session. Nobody’s risking patient outcomes to reduce costs by 0.3%.
The result? Suppliers possess pricing power that pharmaceutical companies can only fantasize about.
And the market treats them like commodity industrial businesses.
Three Structural Dynamics Creating This Opportunity
After analyzing dozens of companies across the medical consumables landscape, I’ve identified three specific factors that make this opportunity particularly compelling right now:
1. Demographic Tailwinds That Are Mathematically Certain
This isn’t speculative. This isn’t hoping for FDA approval or betting on adoption curves.
The U.S. population over 65 is expanding from 58 million today to 82 million by 2040—a 41% increase in the highest-healthcare-consuming demographic cohort.
But the real growth driver is procedure-specific. The interventions that consume the most medical consumables are experiencing explosive growth:
Dialysis patients: Growing 4-5% annually as diabetes and obesity epidemics drive kidney disease prevalence to record levels.
Cardiovascular interventions: Increasing 6-8% per year as the population ages and chronic disease rates climb.
Cancer treatments: Accelerating as detection improves and survival rates extend.
Joint replacements: Booming as baby boomers remain active longer and demand quality of life interventions.
Endoscopy procedures: Expanding with updated colorectal screening guidelines (now starting at age 45 instead of 50).
These aren’t cyclical procedures patients can delay during economic downturns. These are medically necessary interventions that occur regardless of macroeconomic conditions.
Every single procedure requires consumable products used once and reordered perpetually.
2. Industry Consolidation Creating Effective Oligopolies
A decade ago, most consumable categories had 6-8 meaningful competitors. Today, there are typically 2-3 dominant players.
The consolidation drivers are structural:
Regulatory barriers are massive. Maintaining FDA 510(k) clearance and quality management systems costs tens of millions annually. Smaller players cannot sustain the overhead.
Scale economics are decisive. Manufacturing medical-grade consumables requires specialized facilities, validated processes, and enormous working capital. You need global scale to compete profitably.
Procurement is consolidating. Group purchasing organizations (GPOs) now control 90%+ of hospital purchasing. They prefer dealing with 2-3 large, reliable suppliers rather than 10 smaller vendors.
The outcome? The top 2-3 players in each category now control 70-90% of total market share. And they’re not competing on price—they’re competing on reliability, quality, and service consistency.
Which means pricing power continues expanding.
3. Post-COVID Supply Chain Dynamics
Something fundamental changed after the pandemic: hospitals will pay significant premiums to ensure supply continuity for critical consumables.
During COVID, hospitals that prioritized lowest-cost suppliers for items like IV solutions or PPE faced catastrophic supply chain failures. Procedures were delayed. Patients suffered. Executives were terminated.
The lesson was learned permanently. Hospitals are now willing to pay 10-20% premiums to tier-one suppliers who can guarantee uninterrupted supply. They’re signing longer-term contracts. They’re maintaining larger safety stock inventories.
This fundamentally shifted negotiating dynamics. Suppliers aren’t just selling products anymore—they’re selling supply chain insurance. And customers will pay substantial premiums for that certainty.
I spoke with a VP of Supply Chain at a major health system who was explicit: “We used to aggressively negotiate with consumables suppliers every contract cycle. Now we emphasize partnership and reliability. Price is still important, but it’s maybe fourth on our priority list.”
That’s exactly what you want to hear as an investor in these businesses.
The Investment Framework
Not all medical consumables companies are created equal. After analyzing the entire sector, I’m focused on three specific characteristics:
1. High-Volume, Low-Unit-Price Products
This is counterintuitive, but critical.
I don’t want the $50,000 surgical robot or the $10,000 imaging console. I want the $8 syringe and the $35 dialysis filter.
Why?
Purchasing decisions occur at the department level, not executive committees. A $50,000 capital purchase requires extensive approvals, ROI analysis, and board-level scrutiny. An $8 consumable? The department head simply reorders what they’ve always used.
Price increases are invisible. When an $8 product increases to $9, nobody notices or escalates the decision. When a $50,000 device jumps to $55,000, procurement gets involved immediately.
Volume creates compounding switching costs. Once a hospital orders 50,000 units annually of your product, the operational complexity of switching becomes enormous—even though each individual unit is inexpensive.
High-volume, low-unit-price products are simultaneously too small to justify fighting over but too operationally critical to risk changing.
2. Exposure to Non-Discretionary, Chronic-Care Procedures
I want products used in procedures that:
Cannot be medically delayed (dialysis, cardiac interventions, oncology treatment)
Occur repeatedly over years (chronic disease management protocols)
Are driven by demographics and disease prevalence, not economic cycles
Have established clinical evidence and standardized treatment protocols
Elective procedures like cosmetic surgery or LASIK exhibit cyclicality—patients delay them during recessions.
Dialysis for end-stage renal disease? That occurs three times per week, every week, indefinitely. Recession or expansion doesn’t matter.
That’s the procedural exposure I want.
3. Operating Leverage with Margin Expansion Potential
This is where wealth gets created.
These companies have already built:
Manufacturing facilities (largely fixed cost infrastructure)
Distribution networks (established and operational)
Sales organizations (embedded within hospital systems)
Regulatory approvals (complete and maintained)
Now they’re entering a phase where:
Revenue grows 10-15% from combined volume and price increases
But costs only grow 5-7% (fixed cost leverage)
Which drives EBITDA margin expansion of 100-200 basis points annually
And free cash flow compounds at 20-25% annually
This operating leverage—revenue growth flowing through to expanding margins and accelerating cash generation—is what creates multi-bagger returns. Not revenue growth alone.
The Three Companies Positioned to Dominate
I’ve identified three medical consumables companies that satisfy every criterion. Companies where the market fundamentally misunderstands the underlying business quality.
Let me walk through each position.